|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prospective biomarkers of stem cells of human endometrium and fallopian tube compared with bone marrow显示文摘 | Indumathi S Harikrishnan R Rajkumar JS | 2013 | Cell Tissue Res2013，352，3： | 1 |
| 2 | Prospective biomarkers of stem cells of human endometrium and fallopian tube compared with bone marrow 显示文摘 | Indumathi S Harikrishnan R Rajkumar JS | 2013 | Cell Tissue Res2013，352，3： | 1 |
| 3 | Hepatic adenomatosis a rare double complication of multiple adenoma rupture and ma lignant transformation显示文摘 | Arvind N Duraimurugan D Rajkumar JS | 2006 | Indian J Gastroenterol2006，25，4： | 1 |
| 4 | Primary stercoral perforation of the colon-Rare……but deadly显示文摘 | Gowrisankar A Rajkumar JS | 2006 | Indian Journal of Surgery2006，68，1： | 1 |
| 5 | Effectiveness of sustained stretching of the inferior capsule in the management of a frozen shoulder显示文摘 | Paul A Rajkumar JS Peter S | 2014 | Clin Orthop Res2014，472，7： | 1 |
| 6 | Prospective biomarkers of stem cells of human endometrium and fallopian tube compared with bone marrow显示文摘 | Indumathi S Harikrishnan R Rajkumar JS | 2013 | Cell Tissue Res2013，352，3： | 1 |
| 7 | Safety and efficacy of oral HD-03/ES given for six months in patients with chronic hepatitis B virus infection显示文摘AIM: To investigate the safety and efficacy of the formulation HD-03/ES capsules in the management of patients with chronic hepatitis B infection. METHODS: A total of 25 patients were recruited to the study and were given HD-03/ES, two capsules twice daily for six months. Clinical assessment of symptoms and signs were done using the 'clinical observation table' once a month before and after the treatment. Biochemical investigations of total bilirubin, ALT, AST, serum protein for liver function tests were done every month after initiating treatment. Serum was analyzed for HBV markers for HBsAg, HBeAg and HBV DNA at baseline, 4 and 6 mo after therapy using ELISA kits from Roche. RESULTS: After 6 mo of therapy with HD-03/ES, a significant reduction of ALT values from 66.5 ± 11.1 to 39.1 ± 5.2 (P < 0.01) and a significant HBsAg loss (52%, P < 0.001), HBeAg loss (60%, P < 0.05) and HBV DNA loss (60%, P < 0.05) was observed. Adverse effects were mild and never warranted withdrawal of the drug. CONCLUSION: The results of this pilot study indicate that HD-03/ES might be a safe and effective treatment for chronic hepatitis B infection and a long-term multicentric comparator trial is warranted and under way. | JS Rajkumar MG Sekar SK Mitra | 2007 | World Journal of Gastroenterology2007，13，30： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员